1. Home
  2. SWKH vs GNFT Comparison

SWKH vs GNFT Comparison

Compare SWKH & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWKH
  • GNFT
  • Stock Information
  • Founded
  • SWKH 1996
  • GNFT 1999
  • Country
  • SWKH United States
  • GNFT France
  • Employees
  • SWKH N/A
  • GNFT N/A
  • Industry
  • SWKH Diversified Financial Services
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SWKH Finance
  • GNFT Health Care
  • Exchange
  • SWKH Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • SWKH 179.1M
  • GNFT 214.5M
  • IPO Year
  • SWKH 1999
  • GNFT 2019
  • Fundamental
  • Price
  • SWKH $15.04
  • GNFT $3.89
  • Analyst Decision
  • SWKH Strong Buy
  • GNFT Strong Buy
  • Analyst Count
  • SWKH 1
  • GNFT 1
  • Target Price
  • SWKH $18.00
  • GNFT $13.00
  • AVG Volume (30 Days)
  • SWKH 17.4K
  • GNFT 4.2K
  • Earning Date
  • SWKH 08-14-2025
  • GNFT 04-24-2025
  • Dividend Yield
  • SWKH N/A
  • GNFT N/A
  • EPS Growth
  • SWKH 51.50
  • GNFT N/A
  • EPS
  • SWKH 1.41
  • GNFT 0.03
  • Revenue
  • SWKH $34,906,000.00
  • GNFT $73,187,701.00
  • Revenue This Year
  • SWKH $52.93
  • GNFT $15.98
  • Revenue Next Year
  • SWKH N/A
  • GNFT N/A
  • P/E Ratio
  • SWKH $10.70
  • GNFT $125.30
  • Revenue Growth
  • SWKH 18.02
  • GNFT 105.01
  • 52 Week Low
  • SWKH $12.00
  • GNFT $2.55
  • 52 Week High
  • SWKH $16.24
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • SWKH 59.21
  • GNFT 47.15
  • Support Level
  • SWKH $14.56
  • GNFT $3.61
  • Resistance Level
  • SWKH $15.28
  • GNFT $3.95
  • Average True Range (ATR)
  • SWKH 0.34
  • GNFT 0.16
  • MACD
  • SWKH 0.04
  • GNFT -0.03
  • Stochastic Oscillator
  • SWKH 78.57
  • GNFT 44.87

About SWKH SWK Holdings Corporation

SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: